/CGEM
CGEM Stock - Cullinan Therapeutics, Inc.
Healthcare|Medical - PharmaceuticalsNASDAQ
$9.68-3.01%
$0.30 (-3.01%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+237.5%upside
Target: $32.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CGEM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.58 – $9.78
TARGET (TP)$32.67
STOP LOSS$8.91
RISK/REWARD1:29.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.10
52W High$13.33
52W Low$5.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $18.94M | N/A |
| Gross Profit | $-306,000 | N/A | N/A | $18.94M | $-62,000 |
| Gross Margin | N/A | N/A | N/A | 100.0% | N/A |
| Operating Income | $-196,919,000 | $-191,089,000 | $144.65M | $-67,954,000 | $-60,335,000 |
| Net Income | $-167,383,000 | $-153,162,000 | $111.21M | $-65,570,000 | $-51,799,000 |
| Net Margin | N/A | N/A | N/A | -346.1% | N/A |
| EPS | $-3.11 | $-3.69 | $2.46 | $-1.48 | $-1.19 |
Company Overview
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$28
Average Target
↑ 185.8% Upside
Now
$20
Low
$28
Average
$40
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 21st 2025 | H.C. Wainwright | Resumed | Buy | $24 |
| June 11th 2025 | Stifel | Resumed | Buy | $22 |
| October 24th 2024 | UBS | Initiation | Buy | $30 |
| May 1st 2024 | Stifel | Initiation | Buy | $40 |
| April 15th 2024 | William Blair | Initiation | Outperform | - |
| February 15th 2024 | Wedbush | Initiation | Outperform | $30 |
| June 15th 2023 | TD Cowen | Initiation | Outperform | - |
| November 21st 2022 | BTIG Research | Initiation | Buy | $20 |
Earnings History & Surprises
CGEMBeat Rate
67%
Last 18 quarters
Avg Surprise
-3.7%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.77
Q4 2025
EPS Surprise History
Q1 24
+43.7%
$-0.54vs$-0.96
Q2 24
+4.4%
$-0.86vs$-0.90
Q3 24
-2.7%
$-0.75vs$-0.73
Q4 24
+11.5%
$-0.69vs$-0.78
Q1 25
+2.7%
$-0.73vs$-0.75
Q2 25
+5.1%
$-0.74vs$-0.78
Q3 25
-28.9%
$-1.07vs$-0.83
Q4 25
+18.9%
$-0.77vs$-0.95
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.80 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.95 | $-0.77 | +18.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.83 | $-1.07 | -28.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.78 | $-0.74 | +5.1% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.75 | $-0.73 | +2.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.78 | $-0.69 | +11.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.73 | $-0.75 | -2.7% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.90 | $-0.86 | +4.4% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.96 | $-0.54 | +43.7% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.91 | $-0.91 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $-0.99 | $-0.82 | +17.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.84 | $-1.42 | -69.0% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.65 | $-0.59 | +9.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.97 | $-0.54 | +44.3% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $5.47 | $-2.20 | -140.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.61 | $-0.27 | +55.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.47 | $-0.74 | -57.4% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.42 | $-0.36 | +14.3% | ✓ BEAT |
Latest News
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34
📈 PositiveBenzinga•Dec 9, 2025, 01:17 PM
Cullinan Therapeutics shares are trading higher after the company announced updated clinical data from its Phase 1 study of CLN-049 in patients with r/r AML and MDS, which will be presented at the ASH Annual Meeting and Exposition.
📈 PositiveBenzinga•Dec 8, 2025, 04:44 PM
Cullinan Therapeutics Reports CLN-049 Monotherapy Efficacy With Multiple Complete Responses And Durable Activity In Heavily Pretreated R/R AML Patients, Achieves 31% CR/CRh At Highest Dose, Demonstrates Favorable Safety Across Doses; Phase 1 Data Presented At ASH 2025
📈 PositiveBenzinga•Dec 8, 2025, 03:35 PM
Cullinan Therapeutics Says FDA Granted Fast Track Designation To CLN-049 For Treatment Of Relapsed/Refractory Acute Myeloid Leukemia
📈 PositiveBenzinga•Dec 1, 2025, 12:14 PM
Shares of Cullinan Therapeutics are trading higher after BTIG maintained its Buy rating and raised the price target from $32 to $38.
📈 PositiveBenzinga•Nov 24, 2025, 05:47 PM
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $38
📈 PositiveBenzinga•Nov 24, 2025, 05:27 PM
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $38
📈 PositiveBenzinga•Nov 24, 2025, 05:27 PM
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $26
📈 PositiveBenzinga•Nov 20, 2025, 03:53 PM
Taiho Oncology, Taiho Pharma And Cullinan Therapeutics Initiate Rolling Submission Of NDA To FDA Seeking Accelerated Approval Of Zipalertinib For NSCLC Treatment
📈 PositiveBenzinga•Nov 20, 2025, 12:15 PM
Cullinan Therapeutics Q3 EPS $(0.77) Beats $(0.95) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:23 PM
Cullinan Therapeutics shares are trading lower. The company announced new clinical data from its Phase 1 study of CLN-049 in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
📉 NegativeBenzinga•Nov 3, 2025, 06:08 PM
Cullinan Therapeutics To Present New Clinical Data From Phase 1 Study Of CLN-049, Investigational FLT3xCD3 Bispecific T Cell Engager, In Patients With r/r AMLand MDS, At AHS 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:23 PM
Reported Saturday, Cullinan Therapeutics Presents New Preclinical Data Showing CLN-978 Drives Rapid And Deep B Cell Depletion Across Multiple Autoimmune Diseases
📈 PositiveBenzinga•Oct 27, 2025, 06:53 AM
Reported Earlier, Taiho And Cullinan Report Phase 2b Results For Zipalertinib Highlighting 68.8% Intracranial Disease Control And Favorable Safety Profile At ESMO 2025
📈 PositiveBenzinga•Oct 13, 2025, 06:26 AM
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $24 Price Target
📈 PositiveBenzinga•Sep 12, 2025, 10:37 AM
Taiho Oncology And Cullinan Therapeutics Report 27% Response Rate In REZILIENT1 And 30% Response Rate In REZILIENT2 Lung Cancer Trial
📈 PositiveBenzinga•Sep 9, 2025, 09:49 AM
HC Wainwright & Co. Assumes Cullinan Therapeutics at Buy, Announces Price Target of $24
📈 PositiveBenzinga•Aug 21, 2025, 11:29 AM
Morgan Stanley Maintains Overweight on Cullinan Therapeutics, Lowers Price Target to $28
➖ NeutralBenzinga•Aug 18, 2025, 01:12 PM
Morgan Stanley Maintains Overweight on Cullinan Therapeutics, Lowers Price Target to $28
➖ NeutralBenzinga•Aug 18, 2025, 01:12 PM
Frequently Asked Questions about CGEM
What is CGEM's current stock price?
Cullinan Therapeutics, Inc. (CGEM) is currently trading at $9.68 per share. The stock has moved -3.01% today.
What is the analyst price target for CGEM?
The average analyst price target for CGEM is $32.67, based on 1 analyst.
What sector is Cullinan Therapeutics, Inc. in?
Cullinan Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is CGEM's market cap?
Cullinan Therapeutics, Inc. has a market capitalization of $0.57 billion, making it a small-cap company.
Does CGEM pay dividends?
No, Cullinan Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CBLL
CeriBell, Inc.
$21.20
Mkt Cap: $0.8B
EHAB
Enhabit, Inc.
$9.56
Mkt Cap: $0.5B
LAB
Standard BioTools Inc.
$1.63
Mkt Cap: $0.6B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
SY
So-Young International Inc.
$2.88
Mkt Cap: $0.4B
VREX
Varex Imaging Corporation
$12.29
Mkt Cap: $0.5B
Explore stocks similar to CGEM for comparison